TAZ or YAP were activated in the majority of some sarcomas including synovial sarcoma (92%) (Figure 2a), malignant peripheral nerve sheath tumor (90%), uterine leiomyosarcoma (86%), undifferentiated pleomorphic sarcoma (82%) (Figure 2b), Ewing's sarcoma/PNET (80%), non-uterine leiomyosarcoma (78%), myxoid/round cell liposarcoma (78%) (Figure 2c), pleomorphic liposarcoma (71%), high grade osteosarcoma (67%), and alveolar rhabdomyosarcoma (60%) (Figure 2d). Here, YAP1 is linked to primitive neuroectodermal tumor.